AUTHOR INDEX

Beauchamp, R. O. Jr 181
Blundell, J. E. 349
Bocci, V. 1
Bosron, W. F. 59

Colten, H. R. 247
Cooperman, B. S. 271
Crabb, D. W. 59

Dolan, M. E. 167

Eastman, A. 155
Endo, T. 403
Erikson, J. M. 111

Findlay, D. M. 51
Friedlos, F. 215

Gorman, J. J. 51
Groopman, J. D. 321

Halsted, C. H. 453
Heise, C. 453

Kensler, T. W. 321
Kerrigan, D. J. 303

Li, T.-K. 59
Ludlum, D. B. 145

Martin, T. J. 51
Mattern, M. R. 303
McEvoy, M. T. 75
Moseley, J. M. 51

Pegg, A. E. 167
Perlmutter, D. H. 247
Perucca, E. 129
Pommier, Y. 303
Prough, R. A. 111

Richardson, F. C. 181
Roberts, J. J. 215
Ryan, T. J. 335

Stern, R. S. 75
Swenberg, J. A. 181

Tamiya, N. 403
Thurlby, P. L. 349
Tweedie, D. J. 111

Williams, F. M. 99

AUTHOR INDEX

Beauchamp, R. O. Jr 181
Blundell, J. E. 349
Bocci, V. 1
Bosron, W. F. 59

Colten, H. R. 247
Cooperman, B. S. 271
Crabb, D. W. 59

Dolan, M. E. 167

Eastman, A. 155
Endo, T. 403
Erikson, J. M. 111

Findlay, D. M. 51
Friedlos, F. 215

Gorman, J. J. 51
Groopman, J. D. 321

Halsted, C. H. 453
Heise, C. 453

Kensler, T. W. 321
Kerrigan, D. J. 303

Li, T.-K. 59
Ludlum, D. B. 145

Martin, T. J. 51
Mattern, M. R. 303
McEvoy, M. T. 75
Moseley, J. M. 51

Pegg, A. E. 167
Perlmutter, D. H. 247
Perucca, E. 129
Pommier, Y. 303
Prough, R. A. 111

Richardson, F. C. 181
Roberts, J. J. 215
Ryan, T. J. 335

Stern, R. S. 75
Swenberg, J. A. 181

Tamiya, N. 403
Thurlby, P. L. 349
Tweedie, D. J. 111

Williams, F. M. 99

SUBJECT INDEX

Acetylcholinesterase inhibitors, hydrolysis 106
Adverse drug reactions
  psoralens 81, 82
  PUVA 86–89
Affinity chromatography
  monoclonal antibody 326, 327
    human urine 332
    rat urine 329
Aflatoxin B1
  dietary antioxidant, model 327–29
  DNA damage assessment 321–34
  liver cancer 322
  metabolic activation 323
  monoclonal antibody preparation 324-27
  standards, HPLC 330
  structures 322
Alcohol dehydrogenase 61
  factors affecting 66–68
  structure 62
Aldehyde dehydrogenases, ethanol metabolism 64, 65
O^6-Alkylguanine repair 167, 168
O^6-Alkylguanine–DNA alkyltransferase 167–75
  activity 169
  assays 173–75
  distribution 168, 169
  lesion repair 170–72
  reduction 172, 173
  specificity 170–72
Alkylpyrimidine deoxyribonucleosides
  accumulation 202
  alkylation 183
  biological correlates 205–207
  chemicals generating 185–88
  detection methods 189, 190
  diethylnitrosamine 205, 206
  formation, factors influencing 184–89
  misincorporation 194–96
  mutagenesis 191–96
  properties 182–91
  quantitation 190, 191
  removal 204, 205
  repair 196–202
  stability 183, 184
Amino acids
  amino-acid–albumin polymer 10
  antitumor protein degradation 7–10
  clearance times 9
AMSA
  DNA breaks 315–17
  structures 303
Angelicins metabolism 81
Anorectic agents 349–57
  properties 350–54
Anorexia, spontaneous 382
Antibiotics, *E. coli* ribosome effects 289–93
Antitumor agents *see also* protein
Aryltransferases, drug metabolism 101
Aspirin, serum hydrolases 102, 103

Bungarotoxin, conformation 411, 412

Calcitonin
  amino acid sequence 51
  iodination 54
  photoactive 52, 53
  synthesis, salmon 52, 53
Cancer chemotherapy, DNA adducts 145–52, 155–64
Carboplatin half-life 226
Carboxylesterases, drug metabolism 101
Cardiotoxins 408, 408
Catalase 64
Chalones 16, 17
Children, drug metabolism 137–40
Chloramphenicol and ribosome effects 290, 291
Cholinesterases, drug metabolism 99–101
Cisplatin
  cross-linking
    alkaline elution 236–38
    determination 218–38
    formation and loss 230–32, 234, 235
    method comparison 238–41
    method sensitivities 240, 241
    renaturable fraction 232–35
    simulated results 229
    stability 223–27
    X-irradiated sedimentation 227–32
cytotoxicity 215–17
  and cross-linking 241–43
DNA reactions 217, 218
  half-life 226
  hybrid DNA 218–21
CNS lesions and eating behavior 370–73
Cobratoxin conformation 411, 415, 417, 418
Combination therapy, PUVA 89–91
Complement
  activation pathway 249, 250
  C1 260
  C2 252–55
  C3 258–60
  C4 255–58
  C5 258–60
  characteristics 247
  deficiencies 256
  factor B, scheme 252–55
  factor D 260
  membrane attack complex 260, 261
  regulatory proteins 261–63
  scheme 248
Complement gene
  localization 251
  proteins 255
  structure and expression 251, 252
Cytotoxicity, cisplatin and cross-linking 241–43
Cytotoxins *see also* protein, antitumor

DNA
  glutathione cross-linking 162
  platination 169

DNA adducts
  half-lives *in vivo* 200, 201
  HPLC 145–52
  interstrand cross-links 157–61
    characterization 161, 162
  nucleoside release 146, 147
  platinum coordination complex 155–64
    cells 162, 163
  ultraviolet spectra 150
DNA damage assessment 321–34
DNA intercalating agents
  DNA linking number 314–18
  strand break analysis 303–18
DNA strand breaks
  alkaline elution 304
  protein concealed 304–306
DNA supercoiling 310
DNA topoisomerases 304, 306
  nucleoid sedimentation analysis 311–18
Drugs and food intake 349–57 *see also* anorectic agents
  ambivalent effects 357
  enhancement 354–57
  suppressing 350–54
Drug metabolism
  serum enzymes 99–107
  serum hydrolysis 102–106

Eating, experimental manipulation 349–88
Erabutoxin
  conformation 410, 411, 415
  electrostatic potential 435
Ethanol metabolism 59–70
  absorption 59
  and alcohol consumption 68
  elimination curves 59–61
    genetics 69
  enzymes 61–65
  and folate 453
    excretion 455
  hepatobiliary metabolism 454
  intestinal effects 453, 454
  microsomal oxidation 63, 64
  pyridoxine 455–57
  rate, factors affecting 65
  thiamine metabolism 457–59
  vitamin A metabolism 459–61
    and zinc 461

Feeding
  arousal 368, 369
  behavior 358, 359
    micro-structural analysis 361, 362
    structure 369
  castration effects 374, 375
  chemical adjustment 376–78
  CNS lesions 370–73
  continuous monitoring 366
  deprivation-induced 359, 360
  environmental influences 383–88
  genetic adjustments 378–81
  hypophysectomy 375
  intestinal surgery 375
  novelty 366–68
  nutrient self-selection 364–66
  physiological changes and 381–83
  profiles 362–64
  temperature 383
Fetoplacental unit, drug metabolism 129, 130

Fibrinolytic system 335, 336
Folate and ethanol 453–55
Food intake
  diet adjustment 364
  pharmacological suppression 360, 361
Furrocoumarins 75

High-performance liquid chromatography (HPLC)
  chemotherapy, DNA adducts 145–52
    quantitative 151, 152
  DNA adduct separation 147–51
  nucleoside separation 147
  platinum coordinated DNA adducts 157–59
Hydrazine anticancer agents 111–24
  animal studies 111, 112
  enzymology 120–22
  factors affecting 123, 124
  metabolic activation pathways 122, 123
  metabolism
    in vitro 118
    in vivo 117
  mutagenicity 114, 115
  toxicity 113, 114

Immunoglobulins, half-lives 11
Immunotoxins 10–14
  behavior 14
  extravasation 13
Infants, drug metabolism 137–40
Interferons
  cell effects 21
  characteristics 17
  half-lives 18, 19
  inactivation 21
  organ effects 21–23
  pharmacology 20
Interleukins 24, 25

Lysine-binding sites, plasmin and plasminogen 337–40
  role 345

Monoclonal antibodies
  affinity columns and DNA damage 321–34
  half-lives 10–14
MOPP cancer treatment 113

Neocarzinostatin (NCS) properties 15, 16
Neonates, drug metabolism 134–39
  inducibility 137
Neurotoxins, postsynaptic
  amino acid sequences 406, 407
  binding conformational change 433, 434
  conformation 411–22
    crystal and solution 414, 415
  C-terminal tail 429, 430
  definition 403
  dynamic structure 418–20
  fluorescent-labeled 437, 438
  folding 407
  functional residues 427–29
  hydrophobic core 421, 422
  invariant residues 408–10
  primary structure 404
  receptor interaction 437–39
  receptor reactions 422–40

spin-labeled 437
stopped-flow fluorescence 438, 439
structure–function 403–41
structure maintenance 420–22
Nucleoid sedimentation analysis 303–18
DNA compactness 309
DNA topology 307, 308
information 308
topoisomerase hypothesis 311–18
validity 311

Photoaffinity labeling
calcitonin receptor 51–58
plasmin 335–46
properties affected 341–43
technique 341
plasminogen 343–45
procedure 55–58
ribosomes, *E. coli* 271–98
functional centers 293–97
particles 279–81
protein factors 287–89
proteins labeled 275–77
RNA regions labeled 277–82
Plasminogen/plasmin
lysine-binding sites 337–40
role 345
photoaffinity labeling 340–45
Platinum coordination complexes
DNA adducts 155–64
characterization 156
structures 155
Pregnancy
adrenergic blockers 133, 134
antiepileptics 133
drug disposition 130–34
drug metabolism 129–34
plasma clearance 130
Procarbazine
activation pathway 119
chemistry 115–17
degradation pathway 116
metabolism 111–24
structure 112
Prodrugs, serum hydrolysis 105, 106
Proteins, antitumor 1–32 *see also* individual compounds, classes
amino acids degrading 7–10
antigenicity 28
capillary permeability 2
catabolism 4
cytotoxins 4–7
distribution 1, 2, 3
isolation 28
metabolic sites 5
toxicity 30
tumor uptake 29, 30
Protein biosynthesis, reaction sequence on ribosomes 271–73
Psoralens
metabolism 81
pharmacokinetics 79–81
in psoriasis 75–91
Psoriasis
photoimmunology 77–79
psoralen treatment 75–91
PUVA
acute responses 82
adverse effects 86–89
carcinogenicity 86, 87
combination therapy 89–91
immunologic effects 87
mechanism of action 76, 77
pigmented tissues 87, 88
psoriasis treatment 82–86
maintenance 85, 86
results 84
skin types 85

Receptor, acetylcholine
binding region 430–33
mimic structure 431
neurotoxin binding 423–27
species differences 440
structure 422
synthesis 426
Receptor, calcitonin
calcitonin binding 53
photoaffinity labeling 51–58
Receptors, complement C3 263, 264
Ribosomes
anticodon loop 283, 284
functional centers 293–97
functional sites 274
peptidyl transferase 294–96
photoaffinity labeling in *E. coli* 271–98
protein topography 273
mRNA binding center 296, 297
structural studies 271–75
mRNA, photoaffinity labeling 286, 287
tRNA
photoaffinity labeling 282–86
structure 278

Snake venoms 403–41 *see also* neurotoxins
Suxamethonium, serum hydrolysis 104

Thiamine and ethanol metabolism 457–59
Thymic hormones 25, 26
Transfer factor metabolism 26, 27
Tuftsin metabolism 27
Tumor necrosis factor (TNFα) 5, 6

Vitamin A, ethanol effects 459–61
Vitamin B and ethanol 455–57
Vitamin metabolism and ethanol 453–62

Zinc and ethanol 461, 462